Targeted disruption of the B7-H7-PI3K/Akt regulatory axis may inhibit cell proliferation and tumor metastasis, increase sensitivity to RTX, and thereby facilitate the treatment of patients with B-NHL. The gene discussed is AKT1; the disease is neoplasm.